In the United States, medical marijuana has become officially legalized in 33 states and Washington D.C.: representing a collective population that currently exceeds the remainder of the country. Given the rapidly emerging popularity surrounding legalization in the United States, thousands of healthcare providers and clinicians live in geographical areas in which marijuana is legalized. More recently, an October 2018 survey conducted by Pew Research Center indicates that a growing number of Americans support marijuana legalization, with the 62% polled reflecting a steady increase over the past decade.
Healthcare practitioners receive daily questions from patients regarding medical marijuana, yet most remain unequipped to answer any specific queries—given the lack of education concerning clinical cannabis. Most clinicians have received little to no formal training on specific recommendations, dosage protocols, side effects product quality, and potential drug interactions: all critical aspects of patient care, when prescribing medical marijuana.
This workshop is designed to educate attendees—both the novices and regular prescribers—on a variety of medical marijuana-related topics, based on the latest scientific evidence and clinical research. Primary topics incorporated through the workshop's sessions will include the major phytocannabinoids, cannabidiol (CBD), and delta-9-tetrahydrocannabinol (Δ9-THC) found in marijuana and hemp plants. Given that both CBD and Δ9-THC yield unique interactions with the body's endocannabinoid system (ECS), lectures will demonstrate the ways in which phytocannabinoids modulate & influence a variety of physiological systems: including appetite, pain, inflammation, thermoregulation, sensation, muscle control, energy balance, metabolism, sleep hygiene, stress responses, motivation/reward, mood, and memory.
The symposium will conclude with an extended session, during which speakers and leaders from the cannabis industry will provide specific product updates, dosing recommendations, and answer specific “how to prescribe” questions.
Medical Cannabis in 2019:
Rapidly Emerging Clinical Evidence and Effects
Joseph Maroon, MD, FACS
Back to Basics: Medical Cannabis, a History and Overview
Hector Lopez, MD
Stress, Adrenal Health, and Cannabidiol: The ECS-HPA Connection
Aimée Gould Shunney, ND
Cannabis for Common Neurological Conditions
Benefits of Low-THC Marijuana in a Legalized Medical Marijuana State
Deepa Verma, MD
Phytocannabinoids in Addiction, Inflammatory Disorders and Cancer
Kevin Spelman, PhD, MCPP, CNS
Beyond the Hype: CBD Panel Discussion (Non-CME)
Joseph Maroon, MD and Industry Participants
Close of Session